{"id":11370,"date":"2026-01-06T14:12:40","date_gmt":"2026-01-06T06:12:40","guid":{"rendered":"https:\/\/incubator.mcu.edu.tw\/?p=11370"},"modified":"2026-01-06T14:12:40","modified_gmt":"2026-01-06T06:12:40","slug":"the-new-era-of-ai-driven-drug-discovery-symposium","status":"publish","type":"post","link":"https:\/\/incubator.mcu.edu.tw\/en\/11370\/","title":{"rendered":"The New Era of AI- Driven Drug Discovery Symposium"},"content":{"rendered":"<p>Global drug discovery is entering a new era, fundamentally transformed by Artificial Intelligence, data infrastructure, and computational technologies. Traditional R&amp;D is being redefined by predictive analytics and data-driven decision-making, accelerating candidate design and improving efficiency across workflows. Amid rising costs and geopolitical risks, pharmaceutical sovereignty and resilience\u2014a nation&#8217;s ability to independently discover and manufacture critical medicines\u2014have become strategic priorities, with AI as a central pillar.<\/p>\n<p>Against this backdrop, Taiwan is emerging as a key hub for AI-enabled drug discovery, leveraging its strong AI capabilities and world-class healthcare system.<\/p>\n<p>The AI-Driven Drug Discovery Symposium will convene international experts, clinicians, and innovators to explore how AI is reshaping the pharmaceutical value chain, from molecular design to portfolio strategy. Co-hosted by ITRI, Mosaic Venture Lab, A-TEAM HUB, and PwC Taiwan, and featuring global leaders, the event aims to catalyze cross-disciplinary collaboration. Discussions will focus on how Taiwan can strengthen its role through international partnership and data-driven frameworks, advancing the strategic goals of enhancing resilience through collaboration and reducing risk through prediction. We invite you to join this flagship event in early 2026. <\/p>\n<p>Speakers &amp; Panelists<br \/>\nCharlene Hu CEO, GlintMED Accelerator<br \/>\nChe Hsu General Manager, Beiley Biofund<br \/>\nDirk Tomandl CTO, InFocus Therapeutics \/ Ex-Tech Lead, Atomwise<br \/>\nJ\u00e9r\u00e9my Besnard ex-Co-Founder &amp; Chief Designer, Exscientia<br \/>\nJohnny Yu Managing Director, Mosaic Venture Lab (Moderator)<br \/>\nMin-Yi Shih Partner, TCA Venture<br \/>\nMinyuan Chou CTO at Biomedical Technology and Device Research Laboratories, ITRI<br \/>\nNicolas Martin Portfolio Solution Lead, Roche<br \/>\nShih-Li Su Head of BD, Virtualman<br \/>\nYufeng Tseng Executive Director, SPARK Taiwan \/ CEO, Yoda Therapeutics<\/p>\n<p>Agenda \u8b70\u7a0b<br \/>\n13:30 &#8211; 14:00 | Registration \u5831\u5230<br \/>\n14:00 &#8211; 14:20 | Opening Remarks \u958b\u5e55\u81f4\u8a5e\u8207\u5408\u5f71<br \/>\n14:20 &#8211; 15:00 | Keynotes: Data, AI, and Value Creation Across Drug Discovery and Digital Medicine \u6f14\u8b1b<br \/>\n15:00 &#8211; 15:45 | Panel Discussion: AI Reshaping the Drug Discovery Ecosystem \u5ea7\u8ac7\u6703<br \/>\n15:45 &#8211; 16:00 | Tea Break \u4f11\u606f<br \/>\n16:00 &#8211; 16:45 | AIDD Startup Showcase \u65b0\u5275\u7c21\u5831<br \/>\n16:45 &#8211; 17:00 | Closing and Networking \u9589\u5e55\u8207\u4ea4\u6d41<\/p>\n<p>Event Details \u6d3b\u52d5\u8a73\u60c5<br \/>\nDate: Friday, January 23, 2026<br \/>\nVenue: NTUH International Convention Center 402AB (Google Map)<br \/>\n\u65e5\u671f\uff1a2026 \u5e74 1 \u6708 23 \u65e5\uff08\u661f\u671f\u4e94\uff09<br \/>\n\u5730\u9ede\uff1a\u53f0\u5927\u91ab\u9662\u570b\u969b\u6703\u8b70\u4e2d\u5fc3 402AB \u5ef3\uff08\u53f0\u5317\u5e02\u4e2d\u6b63\u5340\u5f90\u5dde\u8def 2 \u865f\uff09<br \/>\nJoin the architects of the AI-driven pharmaceutical future. Space is limited for this curated gathering of ecosystem leaders. (This event will be conducted in English)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Global drug discovery is entering a new era, fundamentally transformed by Artificial Intelligence, data infrastructure, and computational technologies. Traditional R&amp;D is being redefined by predictive analytics and data-driven decision-making, accelerating candidate design and improving efficiency across workflows. Amid rising costs and geopolitical risks, pharmaceutical sovereignty and resilience\u2014a nation&#8217;s ability to independently discover and manufacture critical medicines\u2014have become strategic priorities, with &#8230;<\/p>\n","protected":false},"author":29,"featured_media":11365,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_themeisle_gutenberg_block_has_review":false,"_vp_format_video_url":"","_vp_image_focal_point":[]},"categories":[2],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/incubator.mcu.edu.tw\/en\/wp-json\/wp\/v2\/posts\/11370"}],"collection":[{"href":"https:\/\/incubator.mcu.edu.tw\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/incubator.mcu.edu.tw\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/incubator.mcu.edu.tw\/en\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/incubator.mcu.edu.tw\/en\/wp-json\/wp\/v2\/comments?post=11370"}],"version-history":[{"count":1,"href":"https:\/\/incubator.mcu.edu.tw\/en\/wp-json\/wp\/v2\/posts\/11370\/revisions"}],"predecessor-version":[{"id":11371,"href":"https:\/\/incubator.mcu.edu.tw\/en\/wp-json\/wp\/v2\/posts\/11370\/revisions\/11371"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/incubator.mcu.edu.tw\/en\/wp-json\/wp\/v2\/media\/11365"}],"wp:attachment":[{"href":"https:\/\/incubator.mcu.edu.tw\/en\/wp-json\/wp\/v2\/media?parent=11370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/incubator.mcu.edu.tw\/en\/wp-json\/wp\/v2\/categories?post=11370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/incubator.mcu.edu.tw\/en\/wp-json\/wp\/v2\/tags?post=11370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}